Nasdaq:ENSC
Ensysce Biosciences, Inc.
A synthetic biology biotech firm advancing next-generation treatments for metabolic disorders through proprietary engineering platforms.
Key Metrics
Investment Thesis
Bull Case
The company holds a unique synthetic biology platform capable of producing novel therapeutics for the rapidly expanding obesity market. Recent revenue growth and a narrowing loss trend suggest potential inflection points as products move toward commercialization or licensing milestones. Active capital raises provide necessary runway to de-risk assets and advance clinical candidates without immediate pressure to cut R&D spending.
Bear Case
Operating losses are deep and persistent, with a massive retained earnings deficit signaling the stock is highly speculative and dependent on future fundraising. The company has generated no operating profit and relies entirely on financing activities to survive, creating significant dilution risk for shareholders. Revenue volatility over the past five years demonstrates an unstable business model currently unable to sustain growth independently.
About Ensysce Biosciences, Inc.
Ensysce Biosciences is a biotechnology company focused on developing novel therapeutics for metabolic diseases such as obesity and diabetes. The company leverages proprietary synthetic biology platforms to engineer high-value natural products for pharmaceutical applications. Operations are centered on drug discovery, clinical development, and strategic licensing partnerships within the United States.
Analysis
Management Discussion
The company reported a net loss of $8.0M for 2024, continuing a trend of substantial annual deficits that grew from -$24.2M in 2022 to -$10.6M in 2023 before moderating slightly this year. While revenue surged to $5.2M compared to previous years, the loss narrowed marginally, suggesting some operational efficiency gains amidst high burn rates of nearly $12M including R&D and G&A. Cash flow from operations remained negative at -$7.5M, necessitating continued reliance on financing inflows to maintain liquidity.
Industry Overview
The biotechnology sector for metabolic diseases is experiencing a boom driven by obesity as a major global health crisis and aging patient populations. Companies utilizing synthetic biology are gaining traction by creating scalable manufacturing for high-value biologics that traditional methods cannot replicate. Investors in this space must carefully evaluate balance sheet strength, as many peers face similar liquidity challenges before achieving profitability.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $2.5M | $2.2M | $5.2M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $2.5M | $2.2M | $5.2M |
| Operating Expenses | $26.7M | $12.9M | $11.9M |
| Operating Income | $-24.2M | $-10.7M | $-6.7M |
| R&D | $19.8M | $7.6M | $7.2M |
| G&A | $6.9M | $5.4M | $4.7M |
| Stock-Based Comp | $1.1M | $879.2K | $110.7K |
| Depreciation | — | $0 | $0 |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $109.5K | $353.9K | — |
| Pre-Tax Income | $-24.2M | $-10.7M | $-6.7M |
| Income Tax | $-14.4K | $-91.9K | $1.3M |
| Continuing Ops | $-24.2M | $-10.6M | $-8.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-24.2M | $-10.6M | $-8.0M |
| Minority Interest | $-35.4K | $-13.2K | $-74 |
| Net to Common | $-24.2M | $-10.6M | $-8.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $5.3M | $2.3M | $5.3M |
| Cash & Equivalents | $3.1M | $1.1M | $3.5M |
| Prepaid Expenses | — | $1.1M | $1.7M |
| Other Current Assets | $2.2M | $97.6K | $124.1K |
| Long-Term Assets | $585.9K | $419.2K | $252.6K |
| Total Assets | $5.9M | $2.7M | $5.6M |
| Current Liabilities | $9.5M | $3.3M | $2.2M |
| Accounts Payable | $2.9M | $1.9M | $1.4M |
| Current Leases | $27.3K | — | — |
| Other Current Liab | $6.5M | $1.4M | $850.1K |
| Long-Term Liabilities | $450.5K | $26.4K | $10.1K |
| Total Liabilities | $9.9M | $3.4M | $2.2M |
| Shareholders' Equity | $-4.0M | $-651.3K | $3.4M |
| Paid-In Capital | $107.2M | $121.2M | $133.3M |
| Retained Earnings | $-110.9M | $-121.6M | $-129.5M |
| Total L&E | $5.9M | $2.7M | $5.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-24.2M | $-10.6M | $-8.0M |
| Non-Cash Adjustments | $4.2M | $3.7M | $761.1K |
| Working Capital Changes | $2.1M | $-3.9M | $-276.8K |
| Cash from Operations | $-17.9M | $-10.8M | $-7.5M |
| Cash from Investing | $4.5K | $0 | $0 |
| Cash from Financing | $8.8M | $8.8M | $9.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-9.1M | $-2.0M | $2.4M |
| Beginning Cash | $12.3M | $3.1M | $1.1M |
| Ending Cash | $3.1M | $1.1M | $3.5M |
Frequently Asked Questions
How does Ensysce Biosciences, Inc. make money?
Revenue is primarily derived from product sales in metabolic disease therapies, supplemented by licensing fees and milestone payments from external partners. The company's financial profile reflects heavy investment in research and development costs rather than diversified operational segments.
What are the main risks for ENSC?
Significant and widening operating losses driven by high R&D and administrative expenses totaling over $11M in the latest period. Limited revenue history with only three years of data showing volatility and a recent spike that may not be sustainable. Substantial accumulated retained earnings deficit exceeding $129M indicates long-term burn without consistent profitability. Heavy reliance on external financing given minimal cash reserves relative to ongoing operational needs.
What is ENSC's competitive advantage?
Proprietary synthetic biology platform enabling the engineering of complex natural products not accessible via traditional methods. Strategic focus on high-need therapeutic areas like obesity with potential for significant market growth. Strong cash flow from financing activities indicating active investor interest or strategic capital raises to fund operations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.